EUCR

Eucrates Biomedical Acquisition Corp. [EUCR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EUCR Stock Summary

In the News

EUCR Financial details

Company Rating
Strong Buy
Market Cap
42.23M
Income
5.44M
Revenue
0
Book val./share
2.86
Cash/share
4.15
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2021
P/E
16
Forward P/E
-
PEG
-2.79
P/S
-
P/B
10.2
P/C
-
P/FCF
-67
Quick Ratio
189.93
Current Ratio
2.03
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
0.55
EPS next Y
-
EPS next Q
-
EPS this Y
45.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
100.22%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
3.39%
Inst Trans
0.99%
ROA
44%
ROE
7%
ROC
-0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
4.21M
Shs Float
1.59M
-
-
-
-
Target Price
-
52W Range
9.87-10.25
52W High
-
52W Low
-
RSI
-
Rel Volume
7.64
Avg Volume
1.66K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.074239
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

EUCR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K
Revenue per share
000
Net income per share
00.281.86
Operating cash flow per share
0-0.04-0.21
Free cash flow per share
0-0.04-0.21
Cash per share
0.0404.15
Book value per share
7.597.382.86
Tangible book value per share
7.597.382.86
Share holders equity per share
7.597.382.86
Interest debt per share
00-1.03
Market cap
135.26M131.36M29.77M
Enterprise value
134.71M131.31M29.81M
P/E ratio
15.74K34.355.37
Price to sales ratio
000
POCF ratio
0-261.62-47.22
PFCF ratio
0-261.62-47.22
P/B Ratio
1.321.323.49
PTB ratio
1.321.323.49
EV to sales
000
Enterprise value over EBITDA
15.68K-24.9-11.57
EV to operating cash flow
0-261.52-47.29
EV to free cash flow
0-261.52-47.29
Earnings yield
00.030.19
Free cash flow yield
00-0.02
Debt to equity
000.01
Debt to assets
000
Net debt to EBITDA
-64.150.01-0.02
Current ratio
19.426.872.03
Interest coverage
000.22
Income quality
0-0.13-0.26
Dividend Yield
000
Payout ratio
000
Sales general and administrative to revenue
000
Research and developement to revenue
000
Intangibles to total assets
000
Capex to operating cash flow
000
Capex to revenue
000
Capex to depreciation
000
Stock based compensation to revenue
000
Graham number
0.336.8710.95
ROIC
0-0.01-0.19
Return on tangible assets
00.040.44
Graham Net
-0.24-0.432.83
Working capital
968.77K225.7K67.06K
Tangible asset value
102.11M99.31M8.54M
Net current asset value
-2.7M-5.54M-3.82M
Invested capital
000.01
Average receivables
000
Average payables
000
Average inventory
000
Days sales outstanding
000
Days payables outstanding
000
Days of inventory on hand
000
Receivables turnover
000
Payables turnover
000
Inventory turnover
000
ROE
00.040.65
Capex per share
000

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
0.690.210.070.090.18
Operating cash flow per share
-0.08-0.0100-0.13
Free cash flow per share
-0.08-0.0100-0.13
Cash per share
0.010.010.0104.15
Book value per share
-1.37.487.517.552.86
Tangible book value per share
23.577.487.517.552.86
Share holders equity per share
-1.37.487.517.552.86
Interest debt per share
-0.4-0.09-0.02-0.05-0.12
Market cap
41.13M132.44M133.25M134.86M29.77M
Enterprise value
41.08M132.46M133.33M134.86M29.81M
P/E ratio
3.5511.9136.827.8713.61
Price to sales ratio
00000
POCF ratio
-123.1-945.43-2.45K-3.02K-76.09
PFCF ratio
-123.1-945.43-2.45K-3.02K-76.09
P/B Ratio
-7.491.321.321.333.49
PTB ratio
-7.491.321.321.333.49
EV to sales
00000
Enterprise value over EBITDA
34.24-90.15-233.34-265.16-1.14K
EV to operating cash flow
-122.95-945.62-2.46K-3.02K-76.2
EV to free cash flow
-122.95-945.62-2.46K-3.02K-76.2
Earnings yield
0.070.020.010.010.02
Free cash flow yield
-0.01000-0.01
Debt to equity
00000.01
Debt to assets
00000
Net debt to EBITDA
-0.04-0.02-0.14-0.01-1.57
Current ratio
01.811.10.812.03
Interest coverage
0.290.090.290.240.65
Income quality
-0.28-0.11-0.13-0.09-2.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
4.495.93.373.913.44
ROIC
0.22000-0.12
Return on tangible assets
0.030.030.010.010.04
Graham Net
-1.36-0.33-0.3-0.292.83
Working capital
264.16K158.96K20.28K-22.56K67.06K
Tangible asset value
99.31M100.63M101.06M101.58M8.54M
Net current asset value
-5.54M-4.19M-3.89M-3.83M-3.82M
Invested capital
00000.01
Average receivables
00000
Average payables
00000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.530.030.010.010.06
Capex per share
00000

EUCR Frequently Asked Questions

What is Eucrates Biomedical Acquisition Corp. stock symbol ?

Eucrates Biomedical Acquisition Corp. is a US stock , located in New york of Ny and trading under the symbol EUCR

What is Eucrates Biomedical Acquisition Corp. stock quote today ?

Eucrates Biomedical Acquisition Corp. stock price is $- today.

Is Eucrates Biomedical Acquisition Corp. stock public?

Yes, Eucrates Biomedical Acquisition Corp. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap